Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00614042 · ClinicalTrials.gov registry record · Phase 1
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Aptevo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT00614042 is a Phase 1 study that has completed, run by Aptevo Therapeutics. The registered enrollment target is 96 participants.
The verdict
NCT00614042, a Phase 1 study, has completed, sponsored by Aptevo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of TRU-016 in patients with previously treated chronic lymphocytic leukemia, and to obtain an estimate of clinical activity in patients with CLL and non-Hodgkin's lymphoma.
Interventions
- DRUG TRU-016 (anti-CD37 protein therapeutic)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00614042
The ClinicalTrials.gov registry entry for NCT00614042 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptevo Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRU-016 (anti-CD37 protein therapeutic) is the first listed.
NCT00614042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00614042 about?
NCT00614042 is a clinical study titled "Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma". The purpose of this study is to evaluate the safety and tolerability of TRU-016 in patients with previously treated chronic lymphocytic leukemia, and to obtain an estimate of clinical activity in patients with CLL and non-Hodgkin's lymphoma.
What is the current status of trial NCT00614042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2008-01. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00614042?
The interventions under investigation include: TRU-016 (anti-CD37 protein therapeutic) (DRUG).
Who is sponsoring clinical trial NCT00614042?
This trial is sponsored by Aptevo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.